Trial Profile
A 14 day, randomised, double blinded, placebo-controlled 2-way crossover trial of repeat doses of intranasal GSK256066 and placebo in an environmental exposition unit (Vienna Challenge Chamber) in subjects with seasonal allergic rhinitis (SAR).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Aug 2023
Price :
$35
*
At a glance
- Drugs GSK 256066 (Primary)
- Indications Seasonal allergic rhinitis
- Focus Therapeutic Use
- Sponsors GSK
- 26 May 2011 New trial record